Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Non-Current Assets (2016 - 2025)

Altimmune (ALT) has disclosed Non-Current Assets for 16 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 12.97% to $1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $7.8 million, a 27.62% increase, with the full-year FY2024 number at $2.1 million, up 102.37% from a year prior.
  • Non-Current Assets was $1.8 million for Q3 2025 at Altimmune, down from $1.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $19.1 million in Q1 2021 to a low of $843000.0 in Q1 2024.
  • A 5-year average of $9.7 million and a median of $13.8 million in 2023 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: plummeted 93.97% in 2024, then surged 137.37% in 2025.
  • Altimmune's Non-Current Assets stood at $14.7 million in 2021, then fell by 4.23% to $14.1 million in 2022, then tumbled by 92.82% to $1.0 million in 2023, then soared by 102.37% to $2.1 million in 2024, then dropped by 10.72% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Non-Current Assets are $1.8 million (Q3 2025), $1.9 million (Q2 2025), and $2.0 million (Q1 2025).